Entity

Time filter

Source Type


Do Cao C.,Service dendocrinologie et des maladies metaboliques | Aubert S.,Institute Of Pathologie | Trinel C.,Service dendocrinologie et des maladies metaboliques | Odou M.-F.,Institute Of Biochimie Et Biologie Moleculaire Pole Of Biologie Pathologie Genetique | And 2 more authors.
Annales d'Endocrinologie | Year: 2015

Parathyroid carcinoma is a little-known cancer, difficult to diagnose. We focus this short review on the current diagnostic criteria, the classification and the evaluation tools for this cancer based on latest publications. © 2015 Elsevier Masson SAS. Source


Do Cao C.,Service dendocrinologie et des maladies metaboliques | Mekinian A.,Service dendocrinologie et des maladies metaboliques | Ladsous M.,Service dendocrinologie et des maladies metaboliques | Pattou F.,Service de chirurgie generale endocrinienne | And 2 more authors.
Annales d'Endocrinologie | Year: 2010

Somatostatinoma are rare well-differentiated endocrine tumors with malignant behavior arising from the pancreas and duodenum. They are defined by somatostatin positive immunostaining of the majority of tumor cells. The main clinical features are diabetes, diarrhea and biliary lithiasis related to somatostatin production. Somatostatinoma secreting both calcitonin and somatostatin may be unrecognized as a small number of such observations have been published. We report the case of a 57- year-old woman referred for weight loss, diarrhea and worsening diabetes. Computer tomography scan revealed multiple hypervascular liver lesions suggestive of metastases. High plasma calcitonin level was evidenced, with normal chromogranin-A value, and high plasma somatostatin results lately communicated. Calcitonin secretion of extra-thyroidal origin was suspected leading to the identification of a pancreatic mass by further multiphase CT. The patient underwent left pancreatectomy with surgical hepatic resection. Histological and immunostaining studies confirmed definitive diagnosis of somatostatinoma secreting both somatostatin and calcitonin. Plasma calcitonin should be measured in the assessment of duodeno-pancreatic endocrine neoplasm. Calcitonin determination is available, more reproducible than other specific pancreatic endocrine markers and could be effective for diagnosis and follow-up of such foregut-derived endocrine neoplasia. © 2010 Elsevier Masson SAS. Source

Discover hidden collaborations